West Pharmaceutical Services, Inc.
WST
$230.11
$6.382.85%
Weiss Ratings | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | C | |||
Rating Factors | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | Weak | |||
Growth Index | Fair | |||
Efficiency Index | Excellent | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.42 | |||
Price History | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -1.14% | |||
30-Day Total Return | -32.59% | |||
60-Day Total Return | -30.35% | |||
90-Day Total Return | -27.20% | |||
Year to Date Total Return | -29.89% | |||
1-Year Total Return | -40.49% | |||
2-Year Total Return | -29.00% | |||
3-Year Total Return | -39.86% | |||
5-Year Total Return | 78.48% | |||
52-Week High % Change | -42.60% | |||
52-Week Low % Change | 16.80% | |||
Price | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $400.88 | |||
52-Week Low Price | $197.01 | |||
52-Week Low Price (Date) | Feb 13, 2025 | |||
52-Week High Price (Date) | Mar 21, 2024 | |||
Valuation | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 16.64B | |||
Enterprise Value | 16.46B | |||
Price/Earnings (TTM) | 34.38 | |||
Earnings Per Share (TTM) | 6.69 | |||
Earnings Per Share Growth | -14.97% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 5.83 | |||
Price/Book (Q) | 6.20 | |||
Enterprise Value/Revenue (TTM) | 5.69 | |||
Price | $230.11 | |||
Enterprise Value/EBITDA (TTM) | 21.97 | |||
Enterprise Value/EBIT | 27.73 | |||
Market Cap Category | Large Cap | |||
Dividends and Shares | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 73.30M | |||
Dividend Yield | 0.36% | |||
Div. Per Share (Most Recent) | $0.21 | |||
Dividend Per Share (TTM) | $0.82 | |||
Payout Ratio (TTM) | 12.00% | |||
Dividend Per Share (Most Recent) | $0.21 | |||
Company Info | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 610 594 2900 | |||
Address | 530 Herman O. West Drive Exton, PA 19341-1147 | |||
Website | www.westpharma.com | |||
Country | United States | |||
Year Founded | 1923 | |||
Profitability | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 20.51% | |||
Profit Margin | 17.02% | |||
Management Effectiveness | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 9.93% | |||
Return on Equity | 17.71% | |||
Income Statement | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 2.89B | |||
Total Revenue (TTM) | 2.89B | |||
Revenue Per Share | $39.47 | |||
Gross Profit (TTM) | 998.50M | |||
EBITDA (TTM) | 749.00M | |||
EBIT (TTM) | 593.60M | |||
Net Income (TTM) | 492.70M | |||
Net Income Avl. to Common (TTM) | 492.70M | |||
Total Revenue Growth (Q YOY) | 2.30% | |||
Earnings Growth (Q YOY) | -5.04% | |||
EPS Diluted (TTM) | 6.69 | |||
EPS Diluted Growth (Q YOY) | -2.10% | |||
Balance Sheet | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 484.60M | |||
Cash Per Share (Q) | $6.61 | |||
Total Current Assets (Q) | 1.54B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 2.68B | |||
Current Ratio (Q) | 2.795 | |||
Book Value Per Share (Q) | $37.10 | |||
Total Assets (Q) | 3.64B | |||
Total Current Liabilities (Q) | 550.40M | |||
Total Debt (Q) | 305.30M | |||
Total Liabilities (Q) | 961.10M | |||
Total Common Equity (Q) | 2.68B | |||
Cash Flow | WST - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -378.70M | |||
Cash from Financing (TTM) | -622.60M | |||
Net Change in Cash (TTM) | -369.30M | |||
Levered Free Cash Flow (TTM) | 206.23M | |||
Cash from Operations (TTM) | 653.40M | |||